Project Meeting Prague

Similar documents
Overview of drug-induced deaths in Europe - What does the data tell us?

Cross Border Genetic Testing for Rare Diseases

Smokefree Policies in Europe: Are we there yet?

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

New trends in harm reduction in Europe: progress made challenges ahead

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

European status report on alcohol and health Leadership, awareness and commitment

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

European Collaboration on Dementia. Luxembourg, 13 December 2006

Where do EU Contries set the limit for low risk drinking.

Monthly measles and rubella monitoring report

Where we stand in EFORT

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Trends in injecting drug use in Europe

Perspectives for information on alcohol use in the EU

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Alcohol-related harm in Europe and the WHO policy response

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Nutrient profiles for foods bearing claims

Alcohol in Europe and Brief Intervention. Dr Lars Møller Programme Manager World Health Organization Regional Office for Europe

The cancer burden in the European Union and the European Region: the current situation and a way forward

Engagement in language assessment / Regions of Europe

Underage drinking in Europe

The health economic landscape of cancer in Europe

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

PLACEMENT AND TREATMENT OF MENTALLY ILL OFFENDERS LEGISLATION AND PRACTICE IN EU-MEMBER STATES

Present and potential perspectives for information on alcohol use in the EU

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Outcome of proficiency test on EIA serology

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

European Status report on Alcohol and Health

What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey

The Identification of Food Safety Priorities using the Delphi Technique

LEBANON. WCPT COUNTRY PROFILE December 2018

REPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU

Burden and cost of alcohol, tobacco and illegal drugs globally and in Europe

The Risk of Alcohol in Europe. Bridging the Gap June 2004

DENMARK. WCPT COUNTRY PROFILE December 2018

Transmission, processing and publication of HBS 2015 data

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

UK bowel cancer care outcomes: A comparison with Europe

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

European Community Pharmacy: a reference in Public Health

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

GERMANY. WCPT COUNTRY PROFILE December 2018

Rheumatoid Arthritis Disease Burden and Access to Treatment

CNAPA Meeting Luxembourg September 2016

GERIATRIC TEACHING AND TRAINING IN EUROPE: Where are we? (part I)

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Alcohol Prevention Day

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Q1 What age are you?

real-time AQ data 2007 and plans for 2008

PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY

European Partnership for Screening

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

Palliative nursing care of children and young people across Europe

Development of Palliative Care services in different countries

Note on the harmonisation of SILC and EHIS questions on health

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Extrapolation and potential impact of IPHS deployment in Europe

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

E. Scafato, C. Gandin, L. Galluzzo, S. Ghirini

Building a european consensus on minimum quality standards for drug treatment, rehabilitation and harm reduction

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?

Primary and secondary prevention of sudden cardiac death in emerging economies

EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit

Louis-André Vallet (CNRS) Observatoire Sociologique du Changement (UMR CNRS & Sciences Po Paris)

Review of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes

Risk perception and food safety: where do European consumers stand today?

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

EFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director

Young people and drugs. Analytical report

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY

This document is a preview generated by EVS

Alcohol related harms to children and youth and ways to address it Case of Finland

COMMISSION OF THE EUROPEAN COMMUNITIES

Critical immunity thresholds for measles elimination

A phylodynamic analysis of HIV-1 in Germany

Project BISTAIRS. Deliverable 1b (Work Package 4)

Low risk drinking guidelines in Europe: results from RARHA survey E. Scafato, Istituto Superiore di Sanità, Italy

Transcription:

Project Meeting Prague IO1 Assessment 9.11.217 CHRISTINA PADBERG ON BEHALF OF FRANKFURT UAS

Current Status Assessment matrix was fully evaluated Experts have been interviewed, Interviews were fully evaluated in a matrix Experts: Abrigado, LUX Ministry of Public Health, NL Drobs Bielefeld, GER Drug Aid Vienna, AUS in writing Possible expert interview Latvia could still be pending

Current Status Data Collection and Desk Review are not fully completed yet At some points of the Assessment Report, there is still a lack of data First draft was sent to project partners Review project partners today and until 24th of November 217 (if possible) Second, reviewed version is planned until 4th of December 217

Content List of Figures Introduction 1. Methodology ofthe BeTrAD Project 1.1 Assessment of existing Policies and Services for ageing Drug Users in Europe 1.1.1 Desk Review and Data Collection 1.1.2 Expert Consultation 1.2 The Good Practice Collection 1.3 The Toolbox 1.4 Training 2.1 Desk Review and Data Collection 2.1.1 Problem Opioid Use 2.1.2 Problem Opioid Users over Age of 4 Years 2.1.3 Trajectory of ageing Drug Users 2.1.4 Opioid Substitution Treatment 2.1.5 Problem Use of other illicit Drugs 2.1.6 Specific Services and Methods for ageing Drug Users 2.1.7 Specific Policies for ageing Drug Users 2.1.8 Planned Development of special Policies or Services on ageing Drug Users 2.2 Expert Consultation (Examples) 2.2.1 Development of ageing Drug Users 2.2.2 Specific Services and Methods for ageing Drug Users 2.2.3 Existing Trainings for Staff working with ageing Drug Users 2.2.4 Collaboration between Drug and Geriatric Services 2.2.5 Existing specific national or regional Policies for ageing Drug Users 2.2.6 Planned Developments 2.2.7 Key Barriers and Challenges 3. Recommendations 4. Conclusion 5. Annexes 5.1 Assessment Matrix 5.2 Guiding Questions for Expert Consultation

2.1 Desk Review and Data Collection 2.1.1 Problem Opioid Use Overview: Problem Opioid Use in Europe (EU-28) Country Year of data Total Country Population (15-64 years) Problem Opioid Use Problem Opioid Use over age of 4 years Austria 215/216 5.767.133,5% 47,3% Belgium 215 7.295.584 n.d. about 34%* Bulgaria 215 4.763.637 n.d. n.d. Republic of Croatia 215/216 2.89.119,14% 35% Cyprus 215 584.81,2% about 22%* Czech Republic 215 7.56.824,2% n.d. Denmark 215 3.645.939 n.d. n.d. Estonia 215 858.563 n.d. about 12%* Finland 215 3.483.757,4% about 13%* France 215 41.896.237,5% about 33%* Germany 216/217 53.422.13,3% about 39-4%* Greece 215/216 7.11.27,2% 58% Hungary 216/217 6.664.153,4% about 28%* Ireland 21/215 3.3.481 n.d. about 21%* Italy 215 39.193.416,5% about 48%* Latvia 215 1.33.3,5% about 13%* Lithuania 215 1.948.685 n.d. about 16%* Luxembourg 215 389.371 n.d. about 42%* Malta 215 288.43,6% n.d. Netherlands 216 11.65.975,1% 83% Poland 215 26.431.118,6% about 14%* Portugal 215 6.779.414,5% about 57%* Romania 215 13.414.63 n.d. about 11%* Slovakia 215 3.834.289 n.d. about 18%* Slovenia 215 1.389.178,4% about 2%* Spain 214/215 3.88.472,21% n.d. Sweden 215 6.152.438 n.d. about 49%* United Kingdom 21 41.898.46,8% 34%

2.1 Desk Review and Data Collection 2.1.1 Problem Opioid Use Percentage of Problem Opioid Users over 4 years [%] United Kingdom Sweden Spain Slovenia Slovakia Romania Portugal Poland Netherlands Malta Luxembourg Lithauania Latvia Italy Ireland Hungary Greece Germany France Finland Estonia Denmark Czech Republic Cyprus Republic of Croatia Bulgaria Belgium Austria 2 18 11 14 16 13 21 13 12 22 3 28 33 35 34 4 39 49 48 47,3 57 58 83 1 2 3 4 5 6 7 8 9

Mean Age [in years] 38 37 36 35 34 33 32 Trajectory of mean age of problem opioid users in EU-22* 2.1 Desk Review and Data Collection 2.1.3 Trajectory of ageing Drug Users 31 3 29 25 26 27 28 29 21 211 212 213 214 215 Year *Shifts in the age structure over time of treatment entrants with opioids as primary drug. Only countries with at least 1 years of available data are included (in countries with only 1 years of data, data for most recent year available is copied).

United Kingdom 42,9 Sweden 2.1 Desk Review and Data Collection Spain Slovenia Slovakia Romania Portugal Poland Netherlands Malta 17,5 53,4 6 63 82 91 2.1.4 Opioid Substitution Treatment Luxembourg Lithauania Latvia Italy 1 29,3 Percentage of Users in Opioid Substitution Treatment in EU- 28 [%] Ireland Hungary Greece Germany 17,2 37,6 48,2 Not much data about substitution at all (national level) No data on european level about ageing drug users 4+ (Just Vienna (AUS) 4%, Croatia 44%) France Finland Estonia Denmark Czech Republic Cyprus 21,6 21,7 31,4 8 Republic of Croatia 68,7 Bulgaria Belgium Austria 56 1 2 3 4 5 6 7 8 9 1

2.1 Desk Review and Data Collection 2.1.5 Problem Use of other illicit Drugs Croatia: number of people using other illicit drugs.17%. Percentage of people 4+ about 3% Hungary: 3.9 persons other primary drug than heroin, 1.6% of these people 4+ Canabis: France: 11.1% (15-64 years) problem Canabis user, 22% out of them are 4+ The Netherlands counted 5.4% problematic Canabis user 4+ in 216 MDMA: In nearly all of the european countries there is no data about older user of MDMA MDMA isn t an issue for the target group of ageing users!? Netherlands is counting 6% (decreased from 7%) problem MDMA users over 4 years in 215

2.1 Desk Review and Data Collection 2.1.5 Problem Use of other illicit Drugs Cocaine: On european level cocaine was the next most frequently reported primary drug on drug users over 4 years (17%) Italy: 23% problematic cocaine users over 4 years Spain: 32% The Netherlands: small group of 1.5% problem cocaine users over 4 years Amphetamines: Regarding problematic use, very large group of 57% in Czech Republic, Sweden shows a percentage of 45%, also Finland with a rate of 24% in 215 - The Netherlands were counting just about 1% in the last year No data for users over 4 years

2.1 Desk Review and Data Collection 2.1.6 Specific Services and Methods for ageing Drug Users Rare in Europe - details of data are missing or specific services and methods are not available (Austria, Croatia, Hungary, Spain) Drug aid system seems to be oriented at the needs of younger drug users UK, Bristol: Installed a drug project ( 5 Plus Crowd ) aims to achieve outcomes related to improved health and well-being among older people Greece: Inpatient and outpatient services for this target group are not available, no data about other services Netherlands: Woodstock retirement home (Den Haag) as an inpatient service; outpatient service Enik, a wide and varied training program Best Practice List?

2.1 Desk Review and Data Collection 2.1.7 Specific Policies for ageing Drug Users EU drugs action plan from 29 212 identifies a set of priorities to reduce the demand for drugs, prevention, treatment and harm reduction service - taking account of specific needs (incl. those related to age) In the latest EU Action Plan on Drugs 217-22, ageing and drug use are also mentioned listed as part of drug demand reduction UK and some other countries: older adults are listed as a vulnerable groups for risk of alcohol and drug problems (incl. misuse of medications) No member states drug strategy or other national drug policy has yet created a strategy to deal with older drug users!

2.1 Desk Review and Data Collection 2.1.7 Specific Policies for ageing Drug Users Most European welfare systems are based on improving the financial situation of people in need or to improve their chances of employment or any other aspects, e.g. health or mental health (e.g. economic Models in Austria or Germany, Poland) funding problems The existing welfare models and drug policies poorly serve the needs of older drug users We have no data about specific policies for Croatia, Greece or Hungary. In Germany, Austria, Spain, Luxembourg and the Netherlands, there are no specific policies.

2.1 Desk Review and Data Collection 2.1.8 Planned Development of special Policies or Services on ageing Drug Users The Netherlands: due to political dynamics the current health and social system is under continuous reconstruction because of a new government Spain: Spanish National Strategy for Addictions (currently under draft), special attention to data collection on ageing population to drive the development of services and methods to address ageing drug user s needs Austria: they are only planning a concept for a medical and psychosocial care for non-mobile drug users Hungary or Germany there are no special developments of policies planned at this moment

2.2 Expert Consultation 2.2.1 Development of ageing Drug Users Luxembourg Germany Netherlands Austria Data 217 Abrigado: DROBS Bielefeld: 4-6 years major group 6-7 years manor group Very high rate of opioid users (about 83%) increasing values from users 35-44 y.: 37% in 213 4% in 214 48% in 215 52% in 216 55% in 217 45 y. + : 2% in 213 19% in 214 17% in 215 23% in 216 26% in 217 Since 1-15 years increasing age in low threshold service and substitution service Mean age 4.9 years Mean age substitution 42.5 years Mean age consulting 3.2 years Mean age safe injeciton are 36 22 about 1 substitution patients over 4 212 already 2 persons 215 more than 4% (25 persons) Oldest patient in substitution treatment: 73 years old in 215

2.2 Expert Consultation 2.2.2 Specific Services and Methods for ageing Drug Users Luxembourg Germany Netherlands Austria TABA (213): working project for aging drug users 45+ (max. 2 persons but higher needs) Special inpatient services: LÜSA Unna, Kriegkstraße Frankfurt, FELIX Berlin with outpatient domestic care some inpatient services in elderly care under construction (f.e. Dusseldorf inpatient elderly care for drug users with inpatient nursing care) Not much specific services because of the cure and care system Supported housing for opioid addicted people in most of the big cities (cure and care) like Woodstock with nursery age is 5/55 oldest person 72/73 No specific services, just specialised tools in institutions or services (phone lists, assignment forms)

2.2 Expert Consultation 2.2.3 Existing Trainings for Staff working with ageing Drug Users Luxembourg Germany Netherlands Austria Not available, neither drug Not available, neither drug services nor elderly care services nor elderly care Yes, for elderly care, outpatient nursing care, drug service, doctors Yes, for nursing schools and for addiction care or other interested groups

2.2 Expert Consultation 2.2.4 Collaboration between Drug and Geriatric Services Luxembourg Germany Netherlands Austria Housing first projects are Outpatient care is very often against people who are still taking drugs Outpatient care is difficult because nurses or doctors can t handle the compliance difficult because of the special effort and the uncertainty of the clients (economic reasons, ethical reasons) of ageing drug users Problem: no regulated Medical sector is often rejecting drug users substitution therapy in elderly care services Cure system (treatment/medical sector for addiction problems, psychiatrics, substitution, geriatrics) Care system (support or help in housing, work, daily activities) system of recovery Multidisciplinary neighbourhood teams for people in their own home situation who don t need Cure Nursery care for elderly is very restricted Supported housing Addiction care system Health and social system (nursery care, homeless care, ) Special connection services between health and social system institutions (hospitals) and drug aid system, specialised on addicted people

2.2 Expert Consultation 2.2.5 Existing specific national or regional Policies for ageing Drug Users Luxembourg Germany Netherlands Austria Not available (PSG II) mental illness is now No issue Only treatment guidelines for also part of the rating system nursery care and addiction care 15.3.217 nursing and elderly care is now allowed to offer substitution medicals to patients

2.2 Expert Consultation 2.2.6 Planned Developments Luxembourg Germany Netherlands Austria Actual drug action plan of n/a Heroin assisted treatment: Working group older drug the last 4 years has ageing drug user as topic, evaluation next year Government takes this problem not as important as the practice ageing is an issue there, how can you regulate the continuing of this services on an aging population that is not able to take their substitution medicals by walking (possible question) addicts in Vienna, different parts of the Vienna health and social systems are developing of solutions and best possible care

2.2 Expert Consultation 2.2.7 Key Barriers and Challenges Luxembourg Germany Netherlands Austria Social apartments are Not enough living space: age discrimination in home Integration of older patients missing, drug users need apartments or liberal disability accessed and payable assisted treatments with people and opioid users in health and social system and services housing first models Housing communities with about 35 years same Lack of Cooperation, Abstinence to acceptance possibility of specialised situation as someone who is Networking More low threshold outpatient care and 5 years? More Specific Trainings and substitution treatment cooperation with Very individual care to Education Service for older drug users experienced elderly care support people, not Unregulated away from the younger drug institutions thinking in groups good responsibilities, funding users Improvement of the cooperation between Specific education for nurses and doctors - not just cooperation of elderly care and drug services professionals and professional systems for drug services Appointed rules for offering funding of additional needs for care of drug users in substitutes in elderly care institutions elderly care or nursing Further education for drug No data, more practice research, public relation services, outpatient social support

Open Questions Feedback for the possible interview by Latvia still pending Should there be an overview of the Good Practice Collection? (f.e. point: Special services) More examples in general? Should each country with missing data be mentioned in each topic of the report? Recommendations further procedure? Conclusion? Final correction by native speaker? Marye? Printing of the reports? Deadline? Budget? Online version Regenboog Group?